title: Reappraising the timing of transplant for indolent non-Hodgkin lymphomas.
abstract: BACKGROUND
  Indolent non-Hodgkin lymphomas (iNHL) remain incurable with standard approaches. The timing of autologous stem cell transplant (ASCT) is changing following the introduction of new drugs that can potentially defer the transplant, improved reduced intensity conditioning (RIC) and haploidentical allogeneic SCT (allo-SCT).
  
  
  METHODS
  The most relevant aspects concerning the role of hematopoietic stem cell transplantation in the management of iNHL are discussed. Literature search methodology included examination of PubMed index and meeting presentations. Expert commentary: ASCT is not currently employed as consolidation in first-line, being reserved to patients with refractory/relapsed disease. The curative potential of graft-versus-lymphoma (GVL) after RIC allo-SCT could be particularly beneficial in patients with iNHL relapsing after ASCT. This scenario could be modified in the near future by better definition of high-risk patients at diagnosis, by the improvement of minimal residual disease (MRD) evaluation and by the introduction of new drugs in the therapeutic algorithm.
authors.affiliation: a Hematology, Department of Cellular Biotechnologies and Hematology , Sapienza University , Rome , Italy.
authors.forename: Saveria
authors.initials: S
authors.lastname: Capria
authors.affiliation: a Hematology, Department of Cellular Biotechnologies and Hematology , Sapienza University , Rome , Italy.
authors.forename: Walter
authors.initials: W
authors.lastname: Barberi
authors.affiliation: a Hematology, Department of Cellular Biotechnologies and Hematology , Sapienza University , Rome , Italy.
authors.forename: Salvatore
authors.initials: S
authors.lastname: Perrone
authors.affiliation: a Hematology, Department of Cellular Biotechnologies and Hematology , Sapienza University , Rome , Italy.
authors.forename: Antonietta
authors.initials: A
authors.lastname: Ferretti
authors.affiliation: a Hematology, Department of Cellular Biotechnologies and Hematology , Sapienza University , Rome , Italy.
authors.forename: Adriano
authors.initials: A
authors.lastname: Salaroli
authors.affiliation: a Hematology, Department of Cellular Biotechnologies and Hematology , Sapienza University , Rome , Italy.
authors.forename: Giorgia
authors.initials: G
authors.lastname: Annechini
authors.affiliation: a Hematology, Department of Cellular Biotechnologies and Hematology , Sapienza University , Rome , Italy.
authors.forename: Gianna Maria
authors.initials: GM
authors.lastname: D'Elia
authors.affiliation: a Hematology, Department of Cellular Biotechnologies and Hematology , Sapienza University , Rome , Italy.
authors.forename: Robin
authors.initials: R
authors.lastname: Foà
authors.affiliation: a Hematology, Department of Cellular Biotechnologies and Hematology , Sapienza University , Rome , Italy.
authors.forename: Alessandro
authors.initials: A
authors.lastname: Pulsoni
mesh_terms: D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D019008:Drug Resistance, Neoplasm; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000000981:diagnostic imaging / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D018365:Neoplasm, Residual / Q000175:diagnosis; D000072078:Positron Emission Tomography Computed Tomography; D011379:Prognosis; D012008:Recurrence; D012074:Remission Induction; D061665:Time-to-Treatment; D014019:Tissue Donors; D019172:Transplantation Conditioning; D014182:Transplantation, Autologous; D014184:Transplantation, Homologous; D016896:Treatment Outcome
keywords: ASCT; NHL; allogeneic stem cell transplantation; follicular lymphoma; haploidentical stem cell transplantation; rituximab